Denmark’s Novo Nordisk on Tuesday said new data showed an advantage for type two diabetes patients given its diabetes drug Victoza compared with rival drugs from Merck & Co and Amylin Pharmaceuticals Inc. The world’s biggest insulin producer said in a statement that more type two diabetes patients given Victoza achieved an average blood sugar level below seven percent than those given Merck’s sitagliptin (Januvia) or Amylin’s exenatid BID. For non-diabetics, the usual blood sugar level is between 4 and five percent, while a level of 6.5 percent is considered good blood sugar control for people with diabetes.
